eTheRNA immunotherapies: Funding, Investors & Team (Sep 2026)
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
eTheRNA immunotherapies has raised $38.7M across 1 funding round on record, the most recent a Series B of $38.7M announced in Aug 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
eTheRNA immunotherapies Company Profile and Key Stats
Latest funding round on record: Aug 2022.
eTheRNA immunotherapies Funding Rounds
eTheRNA immunotherapies Founders and Leadership Team
Contact details for the eTheRNA immunotherapies team: 1 of 1 has an email address on file.
Start 14-day free trial →eTheRNA immunotherapies Funding Compared to Other Biotechnology Startups
eTheRNA immunotherapies' latest round of $38.7M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like eTheRNA immunotherapies in Biotechnology and Jette
Companies Similar to eTheRNA immunotherapies
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.
Nyxoah is a health-technology company focused on the development and commercialization of innovative…
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in…
neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their…
Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells,…
Confo Therapeutics is a company focused on drug discovery, specifically targeting GPCRs to address medical…
Animab is a biotech company that focuses on developing unique technology to enhance the health of livestock.…
Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations…
4Tissue is a company focused on research and clinical trials that creates remedies to address the challenges…
Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding…
AgomAb is creating sub-atomic treatments for the recovery of harmed tissues. Their exceptional agonistic…
eTheRNA immunotherapies Funding FAQs
What does eTheRNA immunotherapies do?
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
How much funding has eTheRNA immunotherapies raised?
eTheRNA immunotherapies has raised $38.7M across 1 round on record. The most recent is a Series B of $38.7M announced in Aug 2022.
When did eTheRNA immunotherapies last raise funding?
eTheRNA immunotherapies' most recent funding round on record is a Series B of $38.7M, announced in Aug 2022.
Who is the CEO of eTheRNA immunotherapies?
Steven Powell is listed as CEO at eTheRNA immunotherapies.
Where is eTheRNA immunotherapies headquartered?
eTheRNA immunotherapies is based in Jette, Brussels Hoofdstedelijk Gewest, Belgium.
How many employees does eTheRNA immunotherapies have?
eTheRNA immunotherapies is in the 51-100 employee band.
How does eTheRNA immunotherapies' funding compare to other Biotechnology startups?
eTheRNA immunotherapies' latest round of $38.7M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's eTheRNA immunotherapies Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for eTheRNA immunotherapies is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.